Immunocore and MedImmune Win the SCRIP Award
News Dec 11, 2014
Immunocore Limited has won the Partnership Alliance SCRIP Award 2014 together with its partner, MedImmune, the global biologics research and development arm of AstraZeneca.
The prestigious industry Award recognizes MedImmune’s and Immunocore’s achievements in closing a major strategic partnership agreement at the end of 2013 to research and develop novel cancer therapies using Immunocore’s ImmTAC technology.
Under the terms of the agreement, Immunocore and MedImmune are working together to generate ImmTACs against selected cancer targets. AstraZeneca and MedImmune have the right to further develop and commercialize ImmTAC products to add to their immunotherapy portfolio.
Immunocore received an upfront payment of $20 million per programme and the company is eligible to receive up to $300 million in development and commercial milestone payments for each target programme and significant tiered royalties if the programmes are successful.
Eva-Lotta Allan, Chief Business Officer of Immunocore, commented: “We are delighted to have won the SCRIP Award 2014 together with our partner MedImmune for the Best Partnership Alliance. It is a pleasure to work with the MedImmune team and we look forward to together advancing ImmTAC’s towards the clinic.”
Reginald Seeto, Vice President, Head of Partnering and Strategy, MedImmune, added: “We are very pleased to have received the recognition from the SCRIP Award Judging panel for this creative partnership alliance with Immunocore. Immunocore has a strong track record with its innovative ImmTAC technology, and presents a significant opportunity for us to achieve treatment breakthroughs in the area of immunotherapy.”
Immunocore’s most advanced ImmTAC programme, IMCgp100, is currently in Phase IIa clinical trials in the United States and United Kingdom, in patients with late-stage malignant melanoma.